Inspire Medical Systems (NYSE:INSP – Get Free Report) had its target price hoisted by research analysts at Piper Sandler from $60.00 to $70.00 in a research note issued on Tuesday, Benzinga reports. The firm currently has a “neutral” rating on the stock. Piper Sandler‘s price target would indicate a potential upside of 3.67% from the company’s current price.
INSP has been the subject of several other research reports. Mizuho set a $75.00 price target on shares of Inspire Medical Systems in a research note on Tuesday, October 13th. Robert W. Baird boosted their price objective on shares of Inspire Medical Systems from $54.00 to $59.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. Oppenheimer raised Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a research report on Tuesday, August 4th. Barclays initiated coverage on Inspire Medical Systems in a research note on Tuesday, October 6th. They set an “underweight” rating and a $65.00 price objective for the company. Finally, UBS Group initiated coverage on Inspire Medical Systems in a research note on Tuesday, July 28th. They issued a “sell” rating and a $39.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, Inspire Medical Systems presently has an average rating of “Hold” and an average price target of $71.24.
Get Our Latest Analysis on INSP
Inspire Medical Systems Price Performance
INSP stock opened at $67.52 on Tuesday. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03. The business has a 50 day simple moving average of $68.69 and a two-hundred day simple moving average of $58.82. The company has a market capitalization of $1.95 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 5.37 and a beta of 0.73.
Inspire Medical Systems (NYSE:INSP – Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The company had revenue of $206.69 million during the quarter, compared to analyst estimates of $204.31 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The firm’s revenue was down 7.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.38 earnings per share. Sell-side analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.
Insider Buying and Selling
In related news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares in the company, valued at $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 2.20% of the company’s stock.
Institutional Investors Weigh In On Inspire Medical Systems
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. EverSource Wealth Advisors LLC lifted its stake in Inspire Medical Systems by 1,115.4% during the first quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock worth $33,000 after purchasing an additional 580 shares in the last quarter. Sterling Capital Management LLC grew its stake in shares of Inspire Medical Systems by 450.6% in the third quarter. Sterling Capital Management LLC now owns 914 shares of the company’s stock valued at $63,000 after buying an additional 748 shares in the last quarter. Versant Capital Management Inc grew its stake in shares of Inspire Medical Systems by 379.0% in the second quarter. Versant Capital Management Inc now owns 958 shares of the company’s stock valued at $43,000 after buying an additional 758 shares in the last quarter. Pinnacle Wealth Planning Services Inc. grew its stake in shares of Inspire Medical Systems by 19.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company’s stock valued at $81,000 after buying an additional 194 shares in the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in shares of Inspire Medical Systems by 68.5% in the third quarter. Nisa Investment Advisors LLC now owns 1,200 shares of the company’s stock valued at $83,000 after buying an additional 488 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.
Key Headlines Impacting Inspire Medical Systems
Here are the key news stories impacting Inspire Medical Systems this week:
- Positive Sentiment: Inspire reported third-quarter revenue of approximately $206.7 million, exceeding the $204.3 million consensus estimate. Adjusted earnings of $0.14 per share also topped published estimates of roughly $0.09–$0.10. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
- Positive Sentiment: Management’s commentary pointed toward a potential recovery in the company’s reimbursement environment, which could support procedure volumes and growth if payer-related pressures ease. Inspire Medical Tops Consensus But Misses the Whisper
- Neutral Sentiment: The earnings call was closely watched by analysts for updates on reimbursement, demand and the company’s path back to sustained growth following recent operating challenges. Inspire Medical Systems Q3 2026 Earnings Call Transcript
- Negative Sentiment: Revenue declined 7.9% from the year-ago quarter, while earnings fell to $0.14 per share from $0.38. The results indicate that reimbursement and utilization headwinds remain material despite the quarterly beat. Inspire Medical Systems Q3 Earnings and Revenues Beat Estimates
- Negative Sentiment: Although INSP exceeded official consensus forecasts, reports indicate it missed higher “whisper” expectations, limiting the positive impact of the headline earnings beat and contributing to the weaker share-price reaction. Inspire Medical Tops Consensus But Misses the Whisper
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.
Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.
See Also
- Five stocks we like better than Inspire Medical Systems
- SpaceX Starlink’s Telecom Ground Game Takes Shape
- AST SpaceMobile’s Brazil Breakthrough Could Set the Stage for a Q3 Stock Rebound
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
